Business Context and Reporting Period
Elanco Animal Health Incorporated filed a Form 8-K dated March 25, 2020, under Item 7.01 to disclose additional terms of planned first-lien senior secured credit facilities supporting its anticipated acquisition of Bayer AG’s animal health business.
Financing and Key Financial Metrics
- Total expected senior secured financing: $5.025 billion.
- Term Loan Facility: $4.275 billion principal amount, with a seven-year maturity.
- Revolving Credit Facility: $750 million, with a five-year maturity, including letter-of-credit and swingline sub-facilities.
- Financial maintenance covenants: Expected to apply only for the benefit of revolving-credit lenders; no financial maintenance covenant is expected for the Term Loan Facility.
- Interest coverage covenant: Pro forma adjusted EBITDA to cash interest expense of at least 2.00 to 1.00, tested quarterly beginning September 30, 2020, assuming a July 1, 2020 closing.
- Leverage covenant: A quarterly pro forma net total leverage requirement, beginning September 30, 2020, with the required level based on closing-date pro forma net leverage and pro forma adjusted EBITDA.
The filing does not provide revenue, profit, cash flow, margin, liquidity, or existing debt metrics for the reporting period.
Material Changes Versus Prior Comparable Period
The filing does not present period-over-period operating results. It provides additional clarity regarding financing terms previously priced and disclosed in the Company’s February 4, 2020 Form 8-K.
Guidance, Outlook, Risks, and Unusual Items
The financing and covenant terms are described as expected terms related to the Bayer animal health acquisition and are subject to the completion of the transaction and related documentation. The covenant calculations reference pro forma adjusted EBITDA for the four fiscal quarters ending March 31, 2020, assuming a July 1, 2020 closing.
Key risks include failure or delay in completing the acquisition, inability to obtain debt or equity financing on acceptable terms, integration difficulties or higher-than-expected costs, management distraction, effects on business relationships and operating results, retention of personnel, third-party contract consents, and potential effects on Elanco’s common stock price.
Investor Verification Checklist
- Verify whether the Bayer animal health acquisition closed and the actual closing date.
- Confirm the final financing documents, borrowing amounts, interest rates, maturity dates, and covenant definitions.
- Review actual pro forma leverage, adjusted EBITDA, and cash-interest coverage against the revolving-credit covenants.
- Assess the impact of the additional debt on total leverage, liquidity, refinancing needs, and credit risk.
- Review subsequent SEC filings for changes to the transaction, financing, integration costs, or acquisition-related risks.